Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.

Journal article

Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of a single center study of alemtuzumab as induction in renal transplantation. Thirty-three renal transplant recipients received 20 mg alemtuzumab on day 0 and 1, followed by half-dose cyclosporin monotherapy (trough concentration 75-125 ng/mL) from day 3. They were compared in a retrospective contemporaneous-controlled manner with 66 kidney tra...

Expand abstract

Authors: Watson, C; Bradley, J; Friend, P; Firth, J; Taylor, C

• Publication status: Published
• Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
• Volume: 5
• Issue: 6
• Pages: 1347-1353
• Publication date: 2005-06-01
• DOI: 10.1111/j.1600-6143.2005.00822.x
• EISSN: 1600-6143
• ISSN: 1600-6135
• Language: English
• Keywords: Immunosuppressive Agents; Anti-Inflammatory Agents; Adult; Prednisolone; Postoperative Complications; Remission Induction; Kidney Transplantation; Aged; Cyclosporine; Graft Survival; Time Factors; Safety; Antibodies, Monoclonal; Antineoplastic Agents; Retrospective Studies; Follow-Up Studies; Humans; Antibodies, Monoclonal, Humanized; Treatment Outcome; Drug Therapy, Combination; Female; Antibodies, Neoplasm; Middle Aged; Male; Azathioprine